Cargando…

A novel trivalent HPV 16/18/58 vaccine with anti-HPV 16 and 18 neutralizing antibody responses comparable to those induced by the Gardasil quadrivalent vaccine in rhesus macaque model

Persistent infection with human papillomavirus (HPV) is a key factor in the development of precancerous lesions and invasive cervical cancer. Prophylactic vaccines to immunize against HPV are an effective approach to reducing HPV related disease burden. In this study, we investigated the immunogenic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Yin, Fei, Wang, Yajun, Chen, Na, Jiang, Dunquan, Qiu, Yefeng, Wang, Yan, Yan, Mei, Chen, Jianping, Zhang, Haijiang, Liu, Yongjiang
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2017
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5883244/ https://www.ncbi.nlm.nih.gov/pubmed/28720462 http://dx.doi.org/10.1016/j.pvr.2017.02.005

Ejemplares similares

Cross-neutralizing antibody titres against non-vaccine types induced by a recombinant trivalent HPV vaccine (16/18/58) in rhesus macaques
por: Wang, Yan, et al.
Publicado: (2020)

Construction and immune effect of an HPV16/18/58 trivalent therapeutic adenovirus vector vaccine
por: Wan, Bing, et al.
Publicado: (2022)

A novel vaccine for cervical cancer: quadrivalent human papillomavirus (types 6, 11, 16 and 18) recombinant vaccine (Gardasil(®))
por: Govan, Vandana A
Publicado: (2008)

Impact of HPV vaccination with Gardasil® in Switzerland
por: Jacot-Guillarmod, Martine, et al.
Publicado: (2017)

Incident HPV 51 Infection After Prophylactic Quadrivalent Human Papillomavirus (Types 6, 11, 16, and 18) L1 Virus-Like Particle Vaccine Gardasil/Silgard(®)
por: Halfon, Philippe, et al.
Publicado: (2010)

Relationship between Humoral Immune Responses against HPV16, HPV18, HPV31 and HPV45 in 12-15 Year Old Girls Receiving Cervarix(®) or Gardasil(®) Vaccine
por: Godi, Anna, et al.
Publicado: (2015)

The levels of anti-HPV16/18 and anti-HPV31/33/35/45/52/58 antibodies among AS04-adjuvanted HPV16/18 vaccinated and non-vaccinated Ugandan girls aged 10–16 years
por: Nakalembe, Miriam, et al.
Publicado: (2014)

Stability of trivalent human papillomavirus (types 16, 18, 58) recombinant vaccine (Escherichia coli)
por: Liu, Yu-Ying, et al.
Publicado: (2021)

Update on Safety and Efficacy of HPV Vaccines: Focus on Gardasil
por: Soliman, Monica, et al.
Publicado: (2021)

Increases in HPV-16/18 antibody avidity and HPV-specific memory B-cell response in mid-adult aged men post-dose three of the quadrivalent HPV vaccine
por: Miller, Cheryl N., et al.
Publicado: (2021)

Peak neutralizing and cross-neutralizing antibody levels to human papillomavirus types 6/16/18/31/33/45/52/58 induced by bivalent and quadrivalent HPV vaccines
por: Mariz, Filipe Colaço, et al.
Publicado: (2020)

Quadrivalent Human Papillomavirus (HPV) Types 6, 11, 16, 18 Vaccine for the Prevention of Genital Warts in Males: Profile Report
por: Garnock-Jones, Karly P., et al.
Publicado: (2012)

Genotyping for Human Papillomavirus (HPV) 16/18/52/58 Has a Higher Performance than HPV16/18 Genotyping in Triaging Women with Positive High-risk HPV Test in Northern Thailand
por: Khunamornpong, Surapan, et al.
Publicado: (2016)

Prevalence of HPV 16 and HPV 18 Lineages in Galicia, Spain
por: Pérez, Sonia, et al.
Publicado: (2014)

Safety and immunogenicity of a bivalent HPV16/18 vaccine in Chinese females
por: Shi, Li-Wei, et al.
Publicado: (2023)

Human papillomavirus (HPV) vaccination for the prevention of HPV 16/18 induced cervical cancer and its precursors
por: Damm, Oliver, et al.
Publicado: (2009)

Prevalence of HPV 16 and 18 and attitudes toward HPV vaccination trials in patients with cervical cancer in Mali
por: Téguété, Ibrahima, et al.
Publicado: (2017)

Bivalent Human Papillomavirus (HPV) Vaccine Effectiveness Correlates With Phylogenetic Distance From HPV Vaccine Types 16 and 18
por: Bogaards, Johannes A, et al.
Publicado: (2019)

Is It Time to Genotype Beyond HPV16 and HPV18 for Cervical Cancer Screening?
por: Chua, Brandon Wen Bing, et al.
Publicado: (2022)

Estimated health and economic impact of quadrivalent HPV (types 6/11/16/18) vaccination in Brazil using a transmission dynamic model
por: Kawai, Kosuke, et al.
Publicado: (2012)

A single dose of quadrivalent HPV vaccine is highly effective against HPV genotypes 16 and 18 detection in young pregnant women eight years following vaccination: an retrospective cohort study in Fiji
por: Reyburn, Rita, et al.
Publicado: (2023)

HPV Type 6 and 18 Coinfection in a Case of Adult-Onset Laryngeal Papillomatosis: Immunization with Gardasil
por: Fancello, Virginia, et al.
Publicado: (2015)

Cervarix(™): a vaccine for the prevention of HPV 16, 18-associated cervical cancer
por: Monie, Archana, et al.
Publicado: (2008)

In silico design of a multi-epitope vaccine against HPV16/18
por: Sanami, Samira, et al.
Publicado: (2022)

Development and characterization of an HPV18 detection kit using two novel HPV18 type-specific monoclonal antibodies
por: Zhang, Yao, et al.
Publicado: (2018)

Differences in HPV-specific antibody Fc-effector functions following Gardasil® and Cervarix® vaccination
por: Roy, Vicky, et al.
Publicado: (2023)

Evolution and Taxonomic Classification of Human Papillomavirus 16 (HPV16)-Related Variant Genomes: HPV31, HPV33, HPV35, HPV52, HPV58 and HPV67
por: Chen, Zigui, et al.
Publicado: (2011)

Vaccine efficacy against persistent human papillomavirus (HPV) 16/18 infection at 10 years after one, two, and three doses of quadrivalent HPV vaccine in girls in India: a multicentre, prospective, cohort study
por: Basu, Partha, et al.
Publicado: (2021)

HPV16 and HPV18 Genome Structure, Expression, and Post-Transcriptional Regulation
por: Yu, Lulu, et al.
Publicado: (2022)

Health and economic impact of HPV 16 and 18 vaccination and cervical cancer screening in India
por: Diaz, M, et al.
Publicado: (2008)

Prevalence of cervical infection with HPV type 16 and 18 in Vietnam: implications for vaccine campaign
por: Vu, Lan TH, et al.
Publicado: (2013)

Introduction and sustained high coverage of the HPV bivalent vaccine leads to a reduction in prevalence of HPV 16/18 and closely related HPV types
por: Kavanagh, K, et al.
Publicado: (2014)

Modeling the impact of the difference in cross-protection data between a human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine and a human papillomavirus (HPV)-6/11/16/18 vaccine in Canada
por: Kohli, Michele, et al.
Publicado: (2012)

End-of-study safety, immunogenicity, and efficacy of quadrivalent HPV (types 6, 11, 16, 18) recombinant vaccine in adult women 24–45 years of age
por: Castellsagué, X, et al.
Publicado: (2011)

Absence of HPV 16 and 18 DNA in breast cancer.
por: Wrede, D., et al.
Publicado: (1992)

Monitoring HPV16/18 immunisation in England and elsewhere
por: Franceschi, S
Publicado: (2010)

Significantly Reduced Genoprevalence of Vaccine-Type HPV-16/18 Infections among Vaccinated Compared to Non-Vaccinated Young Women 5.5 Years after a Bivalent HPV-16/18 Vaccine (Cervarix®) Pilot Project in Uganda
por: Kumakech, Edward, et al.
Publicado: (2016)

Triage of HPV-positive women in Norway using cytology, HPV16/18 genotyping and HPV persistence
por: Arbyn, Marc, et al.
Publicado: (2020)

Strong reduction in prevalence of HPV16/18 and closely related HPV types in sexually active adolescent women following the introduction of HPV vaccination in Argentina
por: González, Joaquín Víctor, et al.
Publicado: (2020)

Rapid detection of high-risk HPV16 and HPV18 based on microchip electrophoresis
por: Fan, Zhaoxuan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_5bhg31fnj3vt3oovhu26fn6gl9